Symbol Lookup

Saturday February 25, 2017 10:50 AM ET. Data delayed 15 minutes.
15.03
0.48 (3.30%)
Bid/Lots
15.03/4
Ask/Lots
15.04/5
Open/Prev Close
14.32/14.55
Day Range
14.21-15.40
52-Week Range
4.26-17.20
Vol/Avg Daily Vol
1.3M/1.9M

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
Americans' Favorable Outlook on the Cannabis Market
8:45AM ET on Friday Feb 17, 2017 by PR Newswire
Companies Mentioned: INSY, CARA, CNBX, BLOZF, ZYNE

According to a recent report by Streetwise Reports estimates that the cannabis market crossed $6.7 billion from the U.S. alone in 2016, and that sales of cannabis are set to rise to $22.8 billion in the U.S. by 2020. Despite some concerns regarding how the new administration is going to favor the Cannabis industry, the perception of Americans seems to be shifting. Four states in the U.S. voted in favor of legalization on November 8th of 2016. The results on Election Day confirm that the cannabis industry has a stronger support among Americans than ever before. A study conducted by Pew Research in the U.S. found that the percentage of adults in favor of marijuana legalization is an astounding 57%. Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO.CN), Cannabics Pharmaceuticals Inc. (OTC: CNBX), Insys Therapeutics Inc. (NASDAQ: INSY), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Cara Therapeutics Inc. (NASDAQ: CARA)

According to a recent report by Streetwise Reports estimates that the cannabis market crossed $6.7 billion from the U.S. alone in 2016, and that sales of cannabis are set to rise to $22.8 billion in the U.S. by 2020. Despite some concerns regar...

Feb 7, 2017

FinancialBuzz.com: Legal Cannabis Market Gains Popularity
11:45AM ET on Tuesday Feb 07, 2017 by PR Newswire
Companies Mentioned: INSY, CBDS, CARA, IVITF, ZYNE

The cannabis market is growing rapidly in North American. According to a report from Market Research Future, the North American market size of cannabis is expected to expand at a CAGR over 33% over the period of 2016 to 2021. The report indicates that the U.S., Canada and Mexico are the major markets for cannabis, while the U.S. is the largest one, accounted for 95% of the market size of the North America cannabis market. Canada market is also expected to experience fast growth as the federal government may announce plans to make cannabis legal for recreational use across the entire country in the spring. Invictus MD Strategies Corp. (OTC: IVITF) (CSE: IMH.CN), Cannabis Sativa Inc. (OTC: CBDS), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Insys Therapeutics Inc. (NASDAQ: INSY), Cara Therapeutics Inc. (NASDAQ: CARA)

The cannabis market is growing rapidly in North American. According to a report from Market Research Future, the North American market size of cannabis is expected to expand at a CAGR over 33% over the period of 2016 to 2021. The report indicat...

Feb 3, 2017

Spending on Legal Cannabis Accelerates
9:00AM ET on Friday Feb 03, 2017 by PR Newswire
Companies Mentioned: INSY, CIIX, GWPH, CARA, ZYNE

The rapid growth of the legal cannabis industry could help spur the U.S. economy. According to a report from The Marijuana Policy Group, the legal cannabis market in Colorado alone created about 18,000 cannabis-related jobs in 2015 and generated about $2.39 billion in economic activity for the state. In 2016, cannabis-related companies employed an estimated 100,000 to 150,000 full- and part-time workers, as was indicated in a report by Marijuana Business Daily. Legalization of cannabis for recreational use in four states in 2016 will further fuel the growth of this market. ChineseInvestors.com, Inc. (OTC: CIIX), GW Pharmaceuticals (NASDAQ: GWPH), Cara Therapeutics Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Insys Therapeutics Inc. (NASDAQ: INSY)

The rapid growth of the legal cannabis industry could help spur the U.S. economy. According to a report from The Marijuana Policy Group, the legal cannabis market in Colorado alone created about 18,000 cannabis-related jobs in 2015 and generate...

Peers Headlines

Feb 22, 2017

XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application
8:00AM ET on Wednesday Feb 22, 2017 by GlobeNewswire
Companies Mentioned: XBIT

XBiotech Inc. (NASDAQ:XBIT) announced that all subjects have been dosed in its pharmacokinetic (PK) study evaluating MABp1 half-life in healthy volunteers. This Phase I study will provide further PK data and will enable additional characterizat...

Feb 21, 2017

XBiotech Says Committee Recommends Study of Colorectal Cancer Drug Continues Without Changes
11:24AM ET on Tuesday Feb 21, 2017 by MT Newswires
Companies Mentioned: XBIT
11:24 AM EST, 02/21/2017 (MT Newswires) -- XBiotech (XBIT) shares were higher 6% on Tuesday after the company said an Independent Data Monitoring Committee has performed an analysis of the phase 3 study of its antibody therapy for colorectal canc...
BRIEF-Xbiotech reports affirmative interim analysis of global phase 3 colorectal cancer study
8:46AM ET on Tuesday Feb 21, 2017 by Thomson Reuters
Companies Mentioned: XBIT

Feb 21 (Reuters) - Xbiotech Inc:

* Xbiotech reports affirmative interim analysis of global phase 3 colorectal cancer study

* Xbiotech Inc - IDMC reporte...

BRIEF-Xbiotech reports affirmative interim analysis of global phase 3 colorectal cancer study
8:29AM ET on Tuesday Feb 21, 2017 by Thomson Reuters
Companies Mentioned: XBIT

Feb 21 (Reuters) - Xbiotech Inc:

* Xbiotech reports affirmative interim analysis of global phase 3 colorectal cancer study

* Xbiotech Inc - IDMC reporte...

XBiotech Reports Affirmative Interim Analysis of Global Phase 3 Colorectal Cancer Study
8:00AM ET on Tuesday Feb 21, 2017 by GlobeNewswire
Companies Mentioned: XBIT

XBiotech Inc. (NASDAQ:XBIT) today announced that an Independent Data Monitoring Committee (IDMC) has performed a prospectively planned, unblinded analysis of the Phase 3 XCITE study for the Company's novel candidate antibody therapy for colorec...

Feb 16, 2017

XBiotech's Phase 2 Study of Treatment for HS Meets Primary Endpoint
2:14PM ET on Thursday Feb 16, 2017 by MT Newswires
Companies Mentioned: XBIT
02:14 PM EST, 02/16/2017 (MT Newswires) -- XBiotech (XBIT), a clinical-stage biopharmaceutical company, said Thursday its investigator sponsored randomized Phase 2 study evaluating its True Human antibody, MABp1, as a treatment for Hidradenitis S...
BRIEF-XBIOTECH MEETS PRIMARY ENDPOINT IN PHASE 2 STUDY OF MABP1 FOR TREATMENT OF HIDRADENITIS SUPPURATIVA
11:38AM ET on Thursday Feb 16, 2017 by Thomson Reuters
Companies Mentioned: XBIT

Feb 16 (Reuters) - Xbiotech Inc :

* XBIOTECH MEETS PRIMARY ENDPOINT IN PHASE 2 STUDY OF MABP1 FOR TREATMENT OF HIDRADENITIS SUPPURATIVA (HS)

* XBIOTECH ...

XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa (HS)
11:19AM ET on Thursday Feb 16, 2017 by GlobeNewswire
Companies Mentioned: XBIT

XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human(TM) therapeutic antibodies, today announced topline results from an investigator sponsored randomized Phase 2 study evaluating XBiotech's True Human antibody, MABp1, as a trea...

Feb 13, 2017

Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call
2:45PM ET on Monday Feb 13, 2017 by GlobeNewswire
Companies Mentioned: CLDX

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today upcoming investor events for February and March.

Upcoming Investor Conferences

Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Ex...

Feb 10, 2017

BRIEF-Aglaia Oncology Fund B.V. reports 6.9 percent passive stake in Merus Nv as of December 31, 2016
2:26PM ET on Friday Feb 10, 2017 by Thomson Reuters
Companies Mentioned: MRUS

Feb 10 (Reuters) - Aglaia Oncology Fund B.V.

* Aglaia Oncology Fund B.V. Reports a 6.9 percent passive stake in Merus Nv as of December 31, 2016 - SEC ...

← Newer12Older →